Glutamate Antagonists in Amyotrophic Lateral Sclerosis: A Review of Their Therapeutic Potential

Keyphrases

• Therapeutic Potential 100%
• Glutamate Receptor Antagonists 100%
• Amyotrophic Lateral Sclerosis 100%
• Glutamate 50%
• Motor Neuron 20%
• Synaptic 20%
• Glutamate Release 20%
• Excitatory Transmission 20%
• Weight Loss 10%
• Number of Patients 10%
• Pathophysiology 10%
• Therapeutic Intervention 10%
• Attenuation 10%
• Neurodegeneration 10%
• Brainstem 10%
• Cerebral Cortex 10%
• Neurological Disorders 10%
• Synapse 10%
• Astrocytes 10%
• Symptom Onset 10%
• Spasticity 10%
• Spinal Cord 10%
• Causal Factors 10%
• Glutamate Receptors 10%
• New Anticonvulsant 10%
• Glutamatergic 10%
• Debilitating Disease 10%
• Muscle Weakness 10%
• Glutamate Metabolism 10%
• Excitotoxic 10%
• Glutamatergic Dysfunction 10%
• Glutamatergic Transmission 10%
• Cautious Optimism 10%
• Riluzole 10%
• Therapeutic Gain 10%
• Excitatory Amino Acids 10%
• Rational Therapy 10%
• Nerve Endings 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Glutamate Receptor Antagonist 100%
• Amyotrophic Lateral Sclerosis 100%
• Glutamic Acid 80%
• Diseases 20%
• Neurologic Disease 10%
• Anticonvulsive Agent 10%
• Pathophysiology 10%
• Nerve Degeneration 10%
• Glutamate Receptor 10%
• Spasticity 10%
• Muscle Weakness 10%
• Excitatory Amino Acid 10%
• Riluzole 10%

Neuroscience

• Amyotrophic Lateral Sclerosis 100%
• Glutamic Acid 100%
• Synapse 11%
• Astrocyte 11%
• Neurodegeneration 11%
• Metabolic Pathway 11%
• Cerebral Cortex 11%
• Brainstem 11%
• Nervous System Disorder 11%
• Glutamate Receptor 11%
• Excitatory Amino Acid 11%
• Treatment of Amyotrophic Lateral Sclerosis 11%
• Riluzole 11%
• Anticonvulsant 11%